Erbitux (cetuximab) / Eli Lilly 
Welcome,         Profile    Billing    Logout  
 245 Diseases   389 Trials   389 Trials   11400 News 


«12...5960616263646566676869...143144»
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Biomarker, Clinical, Journal:  Is there any clinical or laboratory predictive factor for cetuximab-induced skin toxicity? (Pubmed Central) -  May 14, 2021   
    Our data for the first time suggest that the natural product β-elemene is a new ferroptosis inducer and combinative treatment of β-elemene and cetuximab is sensitive to KRAS mutant CRC cells by inducing ferroptosis and inhibiting EMT, which will hopefully provide a prospective strategy for CRC patients with RAS mutations. Our study indicate that risk categories based on PLR and RBC can predict CI-ST and de novo metastatic patients had higher risk for CI-ST.
  • ||||||||||  subasumstat (TAK-981) / Takeda
    Trial completion date, Trial primary completion date:  Intratumoral Microdosing of TAK-981 in Head and Neck Cancer (clinicaltrials.gov) -  May 12, 2021   
    P1,  N=12, Recruiting, 
    Our study indicate that risk categories based on PLR and RBC can predict CI-ST and de novo metastatic patients had higher risk for CI-ST. Trial completion date: Mar 2021 --> Sep 2021 | Trial primary completion date: Mar 2021 --> Jun 2021
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    Journal:  Cabozantinib induces PUMA-dependent apoptosis in colon cancer cells via AKT/GSK-3β/NF-κB signaling pathway. (Pubmed Central) -  May 11, 2021   
    Eliminating PUMA expression ablated this apoptosis induced by Cabozantinib in xenograft mouse model. Our findings revealed that Cabozantinib acts to drive CRC cells apoptosis via a PUMA-dependent mechanism, thus identifying PUMA expression as a potential predictor of Cabozantinib efficacy and a potential novel therapeutic target.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Clinical, Journal:  Outcomes Among Minority Patients With Metastatic Colorectal Cancer in a Safety-net Health Care System. (Pubmed Central) -  May 11, 2021   
    HHS provides a health delivery infrastructure through which minority patients with socioeconomic challenges experience clinical outcomes comparable with highly selected patients enrolled in randomized control trials. Efforts to resolve CRC disparities should focus on improving access of at-risk populations to high-quality comprehensive cancer care.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  A thiopyrylium salt for PET/NIR-II tumor imaging and image-guided surgery. (Pubmed Central) -  May 11, 2021   
    Here, a NIR-II thiopyrylium salt, XB1034, was first synthesized and bound to cetuximab and trans-cyclooctene (TCO) to produce XB1034-cetuximab-TCO...Moreover, real-time NIR-II imaging allows accurate tumor excision and sentinel lymph node mapping. In conclusion, XB1034 is a promising molecular imaging probe for tumor diagnosis and treatment.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Retrospective data, Journal:  Is There an Optimal Choice in Refractory Colorectal Cancer? A Network Meta-Analysis. (Pubmed Central) -  May 11, 2021   
    In the RAS WT population, the anti-EGFR drug showed superiority with respect to TAS-102 and regorafenib. These results should be viewed as only exploratory, and further prospective studies are warranted to validate these data.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Herceptin (trastuzumab) / Roche
    Biomarker, Review, Journal:  HER2 as a Predictive Biomarker and Treatment Target in Colorectal Cancer. (Pubmed Central) -  May 11, 2021   
    Although these findings need to be confirmed in randomized trials, the data strongly support that HER2 is an actionable gene in CRC and provide the scientific rationale to test HER2 status on a routine basis in this disease. In this review, we discuss the predictive value of HER2 activation in CRC as well as its potential role as a treatment target.
  • ||||||||||  Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Enrollment change, Trial primary completion date, Metastases:  Bevacizumab/Ph 2 for Locally Advanced Head and Neck Cancer (clinicaltrials.gov) -  May 7, 2021   
    P2,  N=5, Active, not recruiting, 
    CET tends to be superior survival benefit when compared with BEV, with tolerated AEs. N=33 --> 5 | Trial primary completion date: Dec 2021 --> Aug 2020
  • ||||||||||  Bavencio (avelumab) / EMD Serono
    Enrollment closed, Trial completion date, Trial primary completion date, Tumor mutational burden, Metastases:  SAMCO: Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer (clinicaltrials.gov) -  May 7, 2021   
    P2,  N=132, Active, not recruiting, 
    N=33 --> 5 | Trial primary completion date: Dec 2021 --> Aug 2020 Recruiting --> Active, not recruiting | Trial completion date: Mar 2025 --> May 2023 | Trial primary completion date: Feb 2024 --> May 2022
  • ||||||||||  feladilimab (GSK3359609) / GSK
    Trial completion date, Trial primary completion date, Combination therapy, Metastases:  GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors (clinicaltrials.gov) -  May 6, 2021   
    P2,  N=26, Active, not recruiting, 
    Recruiting --> Active, not recruiting | Trial completion date: Mar 2025 --> May 2023 | Trial primary completion date: Feb 2024 --> May 2022 Trial completion date: Feb 2021 --> Jul 2021 | Trial primary completion date: Feb 2021 --> Jul 2021
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Clinical, Review, Journal:  The Landmark Series: Randomized Control Trials Examining Perioperative Chemotherapy and Postoperative Adjuvant Chemotherapy for Resectable Colorectal Liver Metastasis. (Pubmed Central) -  May 6, 2021   
    For patients with resectable CLM, the National Comprehensive Cancer Network Guidelines (version 2.2020) for colon and rectal cancer recommends either upfront surgery and postoperative adjuvant chemotherapy or preoperative chemotherapy followed by surgery and postoperative adjuvant chemotherapy. This article reviews randomized control trials regarding medical therapy before and after curative resection of CLM, and summarizes the updated long-term report of the New EPOC trial which investigated the addition of cetuximab to perioperative chemotherapy for patients with resectable CLM.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Gilotrif (afatinib) / Boehringer Ingelheim
    Trial completion date, Trial primary completion date, Metastases:  Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck (clinicaltrials.gov) -  May 6, 2021   
    P2,  N=50, Recruiting, 
    The results show that up-regulation of miR-125b is associated with higher ORR and DCR and longer survival; let-7c up-regulation and miR-17 down-regulation are associated with higher DCR in mCRC patients treated with anti-EGFR mAbs. Trial completion date: Jan 2021 --> Jan 2022 | Trial primary completion date: Dec 2020 --> Dec 2021
  • ||||||||||  barecetamab (ISU104) / ISU Abxis
    Enrollment closed, Trial completion date, Trial primary completion date, Metastases:  Study of ISU104, Targeting ERBB3 in Patients With Advanced Solid Tumors (clinicaltrials.gov) -  May 6, 2021   
    P1,  N=33, Active, not recruiting, 
    Trial completion date: Jan 2021 --> Jan 2022 | Trial primary completion date: Dec 2020 --> Dec 2021 Recruiting --> Active, not recruiting | Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Jul 2020 --> Oct 2020
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  Definitive chemoradiotherapy plus cetuximab for cancer in the oesophagus or gastro-oesophageal junction. (Pubmed Central) -  May 4, 2021   
    Oxaliplatin and fluorouracil given concurrent with radiotherapy and cetuximab had an acceptable safety profile and showed a clinical response in patients with locoregionally advanced oesophageal cancer unsuitable for surgery. However, the primary end-point was not met, and the addition of cetuximab to definitive chemoradiotherapy cannot be recommended.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  RAC1B modulates intestinal tumourigenesis via modulation of WNT and EGFR signalling pathways. (Pubmed Central) -  May 4, 2021   
    We demonstrate that RAC1B interacts with, and is required for efficient activation of the EGFR signalling pathway. Moreover, RAC1B inhibition sensitises cetuximab resistant human tumour organoids to the effects of EGFR inhibition, outlining a potential therapeutic target for improving the clinical efficacy of EGFR inhibitors in colorectal cancer.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Trial completion date, Trial initiation date, Trial primary completion date, Tumor cell:  Cetuxibab to Reduce Circulating Tumor Cells in Early Stage NSCLC (clinicaltrials.gov) -  May 3, 2021   
    P2,  N=40, Not yet recruiting, 
    Moreover, RAC1B inhibition sensitises cetuximab resistant human tumour organoids to the effects of EGFR inhibition, outlining a potential therapeutic target for improving the clinical efficacy of EGFR inhibitors in colorectal cancer. Trial completion date: Jun 2022 --> Nov 2022 | Initiation date: Jan 2021 --> Jun 2021 | Trial primary completion date: Dec 2021 --> May 2022
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  Penile Cancer-Derived Cells Molecularly Characterized as Models to Guide Targeted Therapies. (Pubmed Central) -  May 1, 2021   
    We also identified CAF signature markers in three PeCa-derived cells with fibroblast-like morphology, indicating that those cells are suitable models for PeCa microenvironment studies. We thus demonstrate the utility of PeCa cell models to dissect mechanisms that promote penile carcinogenesis, which are useful models to evaluate therapeutic approaches for the disease.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Biomarker, Review, Journal:  Biomarker-Guided Anti-Egfr Rechallenge Therapy in Metastatic Colorectal Cancer. (Pubmed Central) -  May 1, 2021   
    The aim of this review is to analyze the current knowledge on rechallenge and to investigate the role of novel biomarkers that can guide the appropriate selection of patients that could benefit from this therapeutic strategy. Finally, we discuss on-going trials and future perspectives.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    [VIRTUAL] Multi-Engineered, iPSC-Derived NK Cells for the Treatment of B-Cell Malignancies () -  Apr 30, 2021 - Abstract #ASGCT2021ASGCT_779;    
    EGFR provides an elimination tag that can be engaged by clinically approved anti-EGFR antibodies, such as Cetuximab...They eliminate HLA-I negative tumor cells comparable to peripheral blood NK cells and when exposed to CD19+ target cells, CAR-iNK cells, they demonstrate potent antigen specific killing that is comparable to conventional CART cells. The multi-engineered iNK cell platform provides a new paradigm for cancer cell therapies through an off-the-shelf product that can be delivered in repeated doses with reduced risk of allo-rejection.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Trial completion:  Efficacy and Safety of the Prophylactic Use of Doxycycline +/- Vitamin K Cream (clinicaltrials.gov) -  Apr 30, 2021   
    P2,  N=124, Completed, 
    These data show the utility of RTK-targeted immunoPET to annotate RTK changes in protein expression and inform tumor response to targeted therapies. Recruiting --> Completed
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Biomarker, Trial completion date, Trial primary completion date, Monotherapy, Metastases:  Cetuximab Maintenance Treatment Versus Continuation After Induction Therapy in mCRC (clinicaltrials.gov) -  Apr 30, 2021   
    P2/3,  N=200, Not yet recruiting, 
    Trial primary completion date: Apr 2021 --> Apr 2022 Trial completion date: Oct 2021 --> Oct 2022 | Trial primary completion date: Oct 2021 --> Oct 2022
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    [VIRTUAL] Online CME closes gaps in CSCC management revealed in a virtual patient simulation. () -  Apr 29, 2021 - Abstract #ASCO2021ASCO_5543;    
    These results demonstrate the effectiveness of curriculum-based education for oncologists to address specific gaps in care as identified in a virtual patient simulation . This series of CME-certified online educational activities resulted in significant improvements in knowledge and competence in the assessment and treatment of patients with CSCC.
  • ||||||||||  [VIRTUAL] Treatment outcomes of recurrent and metastatic adenoid cystic carcinoma: A retrospective analysis. () -  Apr 29, 2021 - Abstract #ASCO2021ASCO_4664;    
    There was no significant difference in the mOS between pts with R/M ACC who were treated with chemo, EGFRi or TKIs and in those who received ICIs compared to those who did not in our limited patient population . This highlights the need for predictive biomarkers for better patient selection with the goal of personalizing treatment strategies for this disease.
  • ||||||||||  Rozlytrek (entrectinib) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
    [VIRTUAL] EGFR blockade leads to singular oncogene-addiction in ETV6-NTRK3 transformed human epithelial cells and hypersensitization to entrectinib. () -  Apr 29, 2021 - Abstract #ASCO2021ASCO_4663;    
    Three different strategies to blockade EGF/EGFR axis including depletion of EGF in culture system, genetic depletion of EGFR using shRNA as well as cetuximab antibody-based EGFR neutralization potentiated oncogene-addiction and hypersensitivity to entrectinib in our models . Together, these findings raise an important question whether blockade of ‘wildtype’ EGFR signaling could improve medical intervention in SC patients presenting with wildtype EGFR and no drug-resistant mutation in entrectinib, by improving oncogene-addiction and attendant hypersensitization of transformed cells to entrectinib.